TriMix - cellular therapy for skin cancer
Publication date 24.01.2012
A new cellular therapy for skin cancer
Over the past few years, cellular therapy and antigen specific immunotherapy have emerged as an efficient treatment of solid tumors.
Since 2002, the department of Medical Oncology at the UZ hospital in Brussels together with the Laboratory for Molecular and Cellular Therapy (LMCT) and the dendritic cell bank of the Medical Faculty of the VUB, have conducted clinical research to evaluate different formulae of dendritic cells in patients with advanced melanoma. Dendritic cells can stimulate the immunity system of patients in such a way that they are able to reject cancer cells.
LMCT, headed by professor Kris Thielemans, has more than 10 years of experience in preclinical research and development of dendritic cells, while Professor Bart Neyns’team in the UZ Medical Oncology department is conducting the clinical trials and follow up of patients.
The most recent clinical trial (phase II) is evaluating the TriMix DC therapeutic vaccination among melanoma patients. The results are extremely positive, and prove that this vaccination is feasible, safe and immunogen and can be combined with other treatments.
Meanwhile, a patent for TriMix has been applied for by the VUB.
Vrije Universiteit Brussel
Laboratory for Molecular and Cellular Therapy (LMCT)
[T] +32 (0)2 477 45 69
[F] +32 (0)2 477 45 6
Head: Kris Thielemans
Scientific contact: Bart Neyns